Tien Dong MD

Officially in print! Our ASTRO Clinical Practice Guideline for #GastricCancer #PracticalRO @AnkerUVMRadOnc @ASTRO_org @SalmaJabbour1 practicalradonc.org/article/S1879-…

Excited to present our poster evaluating the efficacy and safety of the addition of SBRT to atezolizumab and bevacizumab in advanced HCC at #GI24. Thanks to @Salthecancerguy for the 📸

🚨🚨Ph2R Trial of M0 HCC with PVTT (n=90) Comparing: TACE + TKI + SBRT vs. TACE + TKI ✅⬆️ mOS with addition of SBRT☢️ (17.9m vs. 9.6m) ✅⬆️6m PFS with SBRT (78% vs. 36%) 🔥🔥🔥 The data supporting SBRT for localized HCC w/ PVTT continues to pile up!!! #ASCO24

@PBlanchardMD at #SABR2025 - as usual a nuanced, balanced discussion of the role and risks of the role of SABR in head & neck cancers - upfront, in oligomets and re-#radiotherapy #radonc

Dad joke during his introduction: “We have learned the Green Journal will no longer have Peer Review and instead now have Pierre Review”. 😂 #SABR2025

Practical step by step guidance on how to perform pancreatic #SBRT by @lauren_henke at #SABR2025 #SBRT is the best way to deliver BED>100Gy to this tumors, which likely drives superior survival in #PancreaticCancer

📣@DrewMoghanaki - “this talk is going to make some of you uncomfortable”… 🥹 good on you Drew for pushing the boundaries in #lungcancer #radonc - Final talk of #SABR2025 🙏🏽

Really great to see Thoracic Sub-Study of our SARON study presented at #ESTRO25 Simultaneous delivery of CFRT to primary (+/- nodes) & SABR to thoracic mets in synchronous OM-NSCLC ➡️Acceptable acute RT-related adverse events ➡️No grade >3 adverse events observed

Dr. Hoeppner ESOPEC PhIII trial (cT1cN+ or cT2-4acN0/+) esoph adenoCA rand 1:1 periop #FLOT vs neoadj #CROSS ➡️ FLOT superior w/median OS 66 mos vs 37 mos, PFS, & higher pCR (16.8 vs 10%) over CROSS. 52.5% finished adj FLOT, 67.7% finished neoadj CROSS #ASCO24 @OncoAlert

Good q. If decision is for pre-op therapy for T2N0, I’d favor CROSS due to lower treatment burden, cost, & toxicity for most (obviously exact tradeoffs depend on specific scenario). Per ESOPEC forest plot, FLOT ~ CROSS for T2 or N0. Can then add on adjuvant nivo per CM577.

A new publication from @BrendanHeiden et al demonstrates an OS benefit for patients with stage I NSCLC undergoing surgery at VA medical centers with on-site SBRT. The results show that SBRT is being appropriately leveraged to optimize patient selection when available. These data provide further evidence that MDT matters. @ZaidAbdelsattar @kelleymic academic.oup.com/jncics/advance…

@lymberis I am a doctor from Vietnam. Information on induction treatment for cervical cancer is truly important for us. Could you please share the discussion with me?

Watch this informative journal club I hosted dissecting the latest trials in cervical cancer, KEYNOTE-A18 and INTERLACE. We discussed these neoadjuvant and immunotherapy approaches and put in context with MR image guided brachytherapy. Great job to Dr Krystin Bradley, ABS President Elect & Yale RO residents. Free access: bit.ly/4n6NE7m @AmericanBrachy #cervicalcancer #Brachytherapy #journalclub #cervicalcancer #cures #teachingthenextgeneration

A well known thoracic rad onc refused to accept 60Gy/30fx concurrent chemoRT for LS-SCLC as an acceptable treatment regimen on the boards, despite it being the most commonly prescribed fractionation in the US (maybe world?) I will shoot him dirty looks at ASTRO until he apologizes. pubmed.ncbi.nlm.nih.gov/36828750/ pubmed.ncbi.nlm.nih.gov/30219240/

And then there were EIGHT treatment schedules for LS-SCLC studied in randomized clinical trials. #radonc #WCLC25 1) 45/30 (1.5 Gy QD) 2) 60/40 (1.5 Gy BID) 3) 54/30 (1.8 Gy BID) 4) 60/30 (2 Gy QD) 5) 66/33 (2 Gy QD) 6) 70/35 (2 Gy QD) 7) 42/15 (2.8 Gy QD) 8) 45/15 (3 Gy QD)

#WCLC25 Highlights #CommunityOncology: 1. #FLAUR2 1L EGFR mNSCLC @dplanchard 2. #ACROSS2 1L EGFR mNSCLC @JordiRemon 3. #HARMONi 2L EGFR NSCLC 4. #ALCHEMIST Adj ALK+ NSCLC 5. #NadimAdjuvant Adj ChemoIO NSCLC #lcsm #OncTwitter @IASLC @DrJNaidoo @NReguart @IsaOpitz 1/6

🫁 International Association for the Study of Lung Cancer Staging Project 🫁 @JTOonline #WCLC25 #LCSM jto.org/article/S1556-…

#WCLC25 Great summary by @Larvol 👇

@IASLC - WCLC 2025 Recap 🔗 Explore more insights and data from #WCLC25: t.ly/awcNH #LARVOL #CancerResearch #Oncology #ClinicalTrials #LungCancer #WCLC2025 #IASLC #LCSM #NSCLC #SCLC | @HHorinouchi | @diegoadiazg | @StephenVLiu | @lungoncdoc | @Tony_Calles | @ADesaiMD | @M_Torasawa | @SuyogCancer